Positive Feedback Between PGE2 and COX2 Redirects the Differentiation of Human Dendritic Cells Toward Stable Myeloid-derived Suppressor Cells
Overview
Affiliations
Dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs) show opposing roles in the immune system. In the present study, we report that the establishment of a positive feedback loop between prostaglandin E(2) (PGE(2)) and cyclooxygenase 2 (COX2), the key regulator of PGE(2) synthesis, represents the determining factor in redirecting the development of CD1a(+) DCs to CD14(+)CD33(+)CD34(+) monocytic MDSCs. Exogenous PGE(2) and such diverse COX2 activators as lipopolysaccharide, IL-1β, and IFNγ all induce monocyte expression of COX2, blocking their differentiation into CD1a(+) DCs and inducing endogenous PGE(2), IDO1, IL-4Rα, NOS2, and IL-10, typical MDSC-associated suppressive factors. The addition of PGE(2) to GM-CSF/IL-4-supplemented monocyte cultures is sufficient to induce the MDSC phenotype and cytotoxic T lymphocyte (CTL)-suppressive function. In accordance with the key role of PGE(2) in the physiologic induction of human MDSCs, the frequencies of CD11b(+)CD33(+) MDSCs in ovarian cancer are closely correlated with local PGE(2) production, whereas the cancer-promoted induction of MDSCs is strictly COX2 dependent. The disruption of COX2-PGE(2) feedback using COX2 inhibitors or EP2 and EP4 antagonists suppresses the production of MDSC-associated suppressive factors and the CTL-inhibitory function of fully developed MDSCs from cancer patients. The central role of COX2-PGE(2) feedback in the induction and persistence of MDSCs highlights the potential for its manipulation to enhance or suppress immune responses in cancer, autoimmunity, or transplantation.
Li C, Xue Y, Yinwang E, Ye Z Cancer Rep (Hoboken). 2025; 8(2):e70044.
PMID: 39947253 PMC: 11825175. DOI: 10.1002/cnr2.70044.
Wang Q, Yu M, Zhang S Front Immunol. 2025; 15:1440830.
PMID: 39877377 PMC: 11772360. DOI: 10.3389/fimmu.2024.1440830.
Targeting KRAS: from metabolic regulation to cancer treatment.
Shi Y, Zheng H, Wang T, Zhou S, Zhao S, Li M Mol Cancer. 2025; 24(1):9.
PMID: 39799325 PMC: 11724471. DOI: 10.1186/s12943-024-02216-3.
Wang K, Zhang S, Wang Y, Wu X, Wen L, Meng T J Neuroinflammation. 2024; 21(1):307.
PMID: 39609821 PMC: 11603931. DOI: 10.1186/s12974-024-03300-7.
Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells.
Goldmann O, Medina E Front Immunol. 2024; 15:1461455.
PMID: 39534601 PMC: 11554506. DOI: 10.3389/fimmu.2024.1461455.